While immunohistochemical analyses and exomic sequencing are considered gold standards for determining IDH mutational status in gliomas [14,15], tissue heterogeneity, partial sampling of tissue specimens, and the presence of variable amounts of antigens constrain the utility of these methods in the reliable detection of IDH mutational status [16]. The gene discussed is IDH1; the disease is central nervous system cancer.